Introduction
Rituximab is an anti-CD20 monoclonal antibody that has proven to be effective in the treatment of ANCAassociated vasculitis (AAV) in adults. Standard treatments rely on corticosteroids and cyclophosphamide. Only isolated case reports of pediatric AAV treated by rituximab have been reported so far.
Objectives
Our objective was to collect clinical data and outcomes of children with AAV treated with rituximab in a multicenter retrospective study.
Methods
We conducted a retrospective study within the French paediatric rheumatology society (SOFREMIP) in 2011-2012.
Results
We identified 6 children with AAV treated with rituximab (microscopic polyangeitis, n = 2, granulomatosis with polyangeitis, n = 2, unspecified vasculitis, n = 2). The age at onset ranged from 4 to 16 yrs. Treatment with rituximab consisted in 4 infusions of 375 mg/m 2 ; one patient received only 3 infusions. Mean duration of follow-up was 2.65 yrs. All patients achieved clinical remission after 12 months. One patient presented several relapses associated with B cell increase and was dependent on rituximab infusions. No severe adverse event had been reported.
Conclusion
From this multicenter retrospective series, short-term safety and efficicacy of rituximab in pediatric AAV is promising so that B cell depleting agents may represent an alternative to conventional treatment with cyclophosphamide but larger prospective studies are mandatory.
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